StreetInsider.com News Articles

Form 8-K Insight Molecular Diagno For: Jun 11

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659824.html

Form 8-K Insight Molecular Diagno For: Jun 11

Wed, 17 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26659824.html

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship transplant monitoring test, GraftAssure™, and a competing next-generation-sequencing-based assay kit that is sold outside

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry

Tue, 16 Jun 2026 16:05:00 -0400

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitor
GraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring

Form 4 Insight Molecular Diagno For: Jun 11 Filed by: Arno Andrew

Mon, 15 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26648894.html

Form 4 Insight Molecular Diagno For: Jun 11 Filed by: Arno Andrew

Mon, 15 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26648894.html

Form 4 Insight Molecular Diagno For: Jun 11 Filed by: Last Andrew J.

Mon, 15 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26648895.html

Form 4 Insight Molecular Diagno For: Jun 11 Filed by: Last Andrew J.

Mon, 15 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26648895.html

Form 4 Insight Molecular Diagno For: Jun 11 Filed by: SILVERMAN LOU

Mon, 15 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26648896.html

Form 4 Insight Molecular Diagno For: Jun 11 Filed by: SILVERMAN LOU

Mon, 15 Jun 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26648896.html

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

Thu, 11 Jun 2026 16:17:00 -0400

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone
GraftAssure™ assay doubles reliability of positive results in screening cohort
In for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80%

NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced an online published article in the American Journal of Transplantation asserting statistical superiority of the company’s flagship GraftAssure transplant rejection monitoring assay.

IMDx's newly developed GraftAssure Combination Model (CM)-score

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

Thu, 11 Jun 2026 16:17:00 -0400

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone
GraftAssure™ assay doubles reliability of positive results in screening cohort
In for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80%

IMDx's newly developed GraftAssure Combination Model (CM)-score

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

Thu, 11 Jun 2026 16:17:00 -0400

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone
GraftAssure™ assay doubles reliability of positive results in screening cohort
In for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80%

IMDx's newly developed GraftAssure Combination Model (CM)-score

IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

Thu, 11 Jun 2026 16:17:00 -0400

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone
GraftAssure™ assay doubles reliability of positive results in screening cohort
In for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80%

IMDx's newly developed GraftAssure Combination Model (CM)-score

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Tue, 09 Jun 2026 16:05:00 -0400

Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically
Major transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applications
iMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing

NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced it will be highlighting its GraftAssure™ technology at the upcoming American Transplant Congress, to be held in Boston from Saturday, June 20th through Wednesday, June 24th.

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Tue, 09 Jun 2026 16:05:00 -0400

Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically
Major transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applications
iMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Tue, 09 Jun 2026 16:05:00 -0400

Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically
Major transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applications
iMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Tue, 09 Jun 2026 16:05:00 -0400

Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically
Major transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applications
iMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing

BTIG Reiterates Neutral Rating on Insight Molecular Diagnostics Inc. (IMDX)

Fri, 15 May 2026 06:25:33 -0400

BTIG analyst Mark Massaro reiterated a Neutral rating on Insight Molecular Diagnostics Inc. (NASDAQ: IMDX).

The analyst commented: "Insight Molecular Diagnostics is the first company (that we are aware of) to submit to the FDA for a kitted test (in late March 2026) for kidney transplant testing. IMDX is on the clock with the FDA and the company believes it is on track to obtain an FDA approval for its GraftAssureDx kitted transplant test by the end of 2026. We think a decentralized and regulated (FDA-cleared and CE-marked) transplant kitted product should resonate well, particularly OUS, enable labs to run their